August 29, 2018

Media

Media & events

news

Lyndra Therapeutics and Gilead Sciences to Collaborate on Development of Ultra-Long-Acting HIV Therapeutics

July 9, 2019
Lyndra Therapeutics and Gilead Sciences to Collaborate on Development of Ultra-Long-Acting HIV Therapeutics Gilead will have exclusive rights to Lyndra’s...
Read More

publications

  • Changing the Pill: Developments Toward the Promise of an Ultra-Long-Acting Gastroretentive Dosage Form
    Changing the Pill: Developments Toward the Promise of an Ultra-Long-Acting Gastroretentive Dosage Form
Expert Opinion
Expert Opinion
Changing the Pill: Developments Toward the Promise of an Ultra-Long-Acting Gastroretentive Dosage Form
Journal,  Expert Opinion on Drug Delivery ,  Volume 15, 2018 – Issue 12

Changing the pill: developments toward the promise of an ultra-long-acting gastroretentive dosage form

Pages 1189-1198 | Received 17 Jun 2018, Accepted 01 Nov 2018, Accepted author version posted online: 05 Nov 2018, Published online: 13 Nov 2018
URL : View Project

awardS

Lyndra Named as Scrip Award Finalist in Two Categories

Happy to announce our ultra-long acting oral dosage form has been named a finalist for the Scrip MSD Innovation Award, and our co-founder Amy Schulman has been named a finalist in the Executive of the Year category!

#ScripAwards

Amy Schulman, Lyndra Co-founder and CEO, honored on 2019 PharmaVOICE 100

“Amy’s fearless approach to create durable value and change the trajectory of compliance for some of most difficult to treat diseases —  Alzheimer’s disease, HIV, opioid use disorder, and schizophrenia — are just a couple of the reasons she has been identified as one of the 100 most inspiring people in the life-sciences industry,” says Taren Grom, editor, PharmaVOICE

#PharmaVOICE

2019 Xconomy Awards Finalist in Startup Category

We are honored to be named a finalist for the Awards in the category for our work making daily pills a thing of the past.

#XconomyAwards

events

Lyndra Presents @ BIO International

Join us on Thursday, June 5th, at 5pm when Andrew Bellinger, our CSO, presents our 2019 Company Update at BIO International, Philadelphia Convention Center, Theater 4

2019 BIO International